Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVR1 | Q04771 | 13/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 9/20 | 0.42 |
| ▸ | FYN | P06241 | 1/20 | 0.41 |
| ▸ | NOD2 | Q9HC29 | 5/20 | 0.39 |
| ▸ | RIPK2 | O43353 | 4/20 | 0.39 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL68061 | 0.86 | PRMT5 (0.35) | ACVR1FYNNOD2RIPK2 | |
| SCHEMBL84579 | 0.79 | DGAT1 (0.39) | FYN | |
| SCHEMBL4842921 | 0.78 | HTR2C (0.38) | — | |
| SCHEMBL67109 | 0.78 | TNIK (0.43) | FYNALK | |
| SCHEMBL68342 | 0.74 | PIM1 (0.41) | — | |
| SCHEMBL68587 | 0.73 | PRMT5 (0.34) | ACVR1FYNNOD2RIPK2 | |
| SCHEMBL5201005 | 0.70 | HTR2C (0.34) | — | |
| SCHEMBL15181498 | 0.68 | DGAT1 (0.40) | — | |
| SCHEMBL4853070 | 0.68 | HTR2C (0.38) | — | |
| SCHEMBL4847436 | 0.67 | HTR2C (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865732-B2 | Heterocyclic compounds and uses thereof | NOVARTIS AG (CH) | 2014-10-21 | — | — | US | disclosed |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | NOVARTIS AG (CH) | 2013-08-15 | — | — | US | disclosed |
| US-8129394-B2 | Heteroaryl-substituted imidazole compounds and uses thereof | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| EP-2274300-A2 | NOVEL HETEROCYCLIC COMPOUNDS AND USES THEROF | Novartis AG (CH) | 2011-01-19 | — | — | EP | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
| WO-2009115572-A2 | NOVEL HETEROCYCLIC COMPOUNDS AND USES THEROF | NOVARTIS AG (CH) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | BRAF, ARAF, KRAS | ACVR1 3334/4885TGFBR1 4497/4885FYN 628/4885 |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | BRAF, RAF1, HRAS | ACVR1 2882/4885TGFBR1 4502/4885FYN 520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.